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Abstract: Background: Cystic fibrosis (CF) is a hereditary disorder in which persistent unresolved
inflammation and recurrent airway infections play major roles in the initiation and progression of
the disease. Little is known about triggering factors modulating the transition to chronic microbial
infection and inflammation particularly in young children. Cystic fibrosis respiratory disease
starts early in life, with the detection of inflammatory markers and infection evident even before
respiratory symptoms arise. Thus, identifying factors that dysregulate immune responsiveness
at the earliest stages of the disease will provide novel targets for early therapeutic intervention.
Methods: We evaluated the clinical significance of bile acid detection in the bronchoalveolar lavage
fluid of clinically stable preschool-aged children diagnosed with CF. Results: We applied an unbiased
classification strategy to categorize these specimens based on bile acid profiles. We provide clear
associations linking the presence of bile acids in the lungs with alterations in the expression of
inflammatory markers. Using multiple regression analysis, we also demonstrate that clustering
based on bile acid profiles is a meaningful predictor of the progression of structural lung disease.
Conclusions: Altogether, our work has identified a clinically relevant host-derived factor that may
participate in shaping early events in the aetiology of CF respiratory disease.
Keywords: cystic fibrosis; bile acids; gut-lung axis
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1. Introduction
Cystic fibrosis (CF) is an autosomal recessive condition caused by pathogenic genetic variants
that compromise the function of the cystic fibrosis conductance transmembrane regulator (CFTR) gene
product [1]. At the molecular level, the pathogenesis resulting from CFTR dysfunction involves
the hyper-production of inspissated mucous secretions, which impact the integrity and function
of the airway epithelial barrier [2,3]. In agreement with the widespread expression of CFTR [4],
the clinical presentation of CF patients is linked to pleiotropic defects including pancreatic insufficiency,
intestinal obstruction or liver and chronic airway disease.
Cystic fibrosis lung disease is characterized by chronic neutrophilic inflammation and infection,
which progressively lead to the development of bronchiectasis, lung function decline and ultimately
respiratory failure [5,6]. This progressive course is marked by a succession of unpredictable episodic
clinical deteriorations known as acute pulmonary exacerbations, the aetiology of which is not well
understood [7–9]. Therefore, delineating the factors predisposing CF patients to airway inflammation
and infection in early life is a necessary prerequisite for improvements in the clinical management of
respiratory lung disease particularly in children.
Apart from the evident respiratory phenotype, most chronic respiratory conditions develop
parallel intestinal complications suggesting the existence of a gut-lung communication axis that can
deliver aetiological factors into the lung epithelia [10,11]. These studies not only imply the existence
of a bidirectional communication axis between both body sites through which alterations in one
environment would be transmitted to the other, but also suggest common aetiological factors for both
types of illnesses [10,11]. The most common gastrointestinal co-morbidity in chronic airway disease is
duodenogastro-esophageal reflux, which has been associated with respiratory symptoms and disease
progression in many respiratory conditions [12–15].
Among potential host triggers that may be implicated in modulating host-microbiota interactions
and inflammation in the CF lung through the gut-lung axis, bile acids (BAs) have been demonstrated to
influence both biofilm formation and antibiotic tolerance in a number of respiratory pathogens [16–18].
Bile acids have also been demonstrated to regulate the immune response of airway epithelial cells
by repressing HIF1 signalling through destabilisation of HIF1-α and inducing the production of the
pro-inflammatory cytokine interleukin 6 (IL6) [16,19]. We also observed that production of IL6 is
regulated through the functional modulation of the BA receptor farnesoid X receptor (FXR) [16,19].
Bile acids are a key component of the gastric refluxate and are thought to gain entry into the CF lung
through a (micro)aspiration process often associated with gastroesophageal reflux, which is a highly
prevalent condition in CF patients [12,20–22].
The aim of this study was to evaluate whether the presence of BAs in the bronchoalveolar
lavage fluid (BALF) of clinically stable preschool-aged children diagnosed with CF, was associated
with markers of inflammation and clinical outcomes. In this work, we report a number of striking
associations between the presence of BAs in the BALF of paediatric CF patients and the increase of
proinflammatory cytokines. We also provide a statistical model validating BA detection in BALF as
a significant predictor for accelerated progression of structural lung disease. Collectively these new
data suggest that BAs could act to influence early events in the aetiology of CF respiratory disease.
Progressing to dissect the CF lung-bile acid-inflammation axis will provide a mechanistic basis to
address the pulmonary disease heterogeneity issue that is characteristic even in very early disease.
2. Material and Methods
2.1. BALF Collection, Cytology and Cytokine Measurements
BALF samples were collected according to the AREST-CF standard operating protocols [23].
Three washes of saline were lavaged into the right middle lobe (RML), and then one wash into the
second most affected lobe determined by CT scan (usually lingula) [23]. Clinical microbiology was
performed on the first RML and the left lobe washes [23]. The second and third RML lavage were
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pooled and processed into eukaryotic cells and supernatant. Viability of white cell lineages was
determined using 0.1% trypan blue staining. Differential cell counts and cytokine measurements were
previously described [23–25].
2.2. Bile Acid Profiling
BALF samples were treated with equal volumes of Sputolysin® (Calbiochem, Darmstadt, Germany)
and processed as described previously [16,26]. Each BALF sample was analysed blinded to patient data
for the presence of 12 principal bile acids compared to purified reference standards. Cholic acid (CA),
chenodeoxycholic acid (CDCA), deoxycholic acid (DCA), lithocholic acid (LCA), ursodeoxycholic acid
(UDCA), glycodeoxycholic acid (GDCA), taurochenodeoxycholic acid, (TCDCA), taurodeoxycholic
acid (TDCA), taurocholic acid (TCA), glycocholic acid (GCA), taurolithocholic acid (TLCA) were
purchased from Sigma-Aldrich (Buchs, Switzerland) and tauroursodeoxycholic acid (TUDCA) was
purchased from Calbiochem. All chemicals used were HPLC grade.
2.3. Statistical Analysis
Statistical analysis was carried out in R (version 3.4.2, R Foundation for Statistical Computing,
Vienna, Austria) [27]. Hierarchical clustering was performed with the built-in function hclust using
Ward’s criterion [28,29]. Silhouette information was obtained with the silhouette function of the
package cluster [30]. Calinski-Harabasz index was calculated with the NbClust function of the
package NbClust [31]. Principal component analysis was performed with the built-in function prcomp,
which uses singular value decomposition for computation of the principal components. Contribution of
each variable to the first principal component was calculated from the squared loadings for variables.
Linear regression was performed using the built-in function glm using a Gaussian model and the
identity link function. Linear mixed effect models were fitted using the lme function of the package
lme4 [32]. Unless otherwise stated in the text and accordingly to widespread consensus, statistical tests’
null hypothesis was rejected when p-values were lower than 0.05.
2.4. Ethics, Consent and Permissions
Ethical approval (Ref. 1762/EPP) was previously granted to the AREST-CF program by the
Princess Margaret Hospital for Children, Perth ethics committee (10 December 2009) and written
informed consent for publication was obtained to participate from parents/guardians. All methods
performed in this study were carried out in accordance with the relevant guidelines and regulations
2.5. Data Availability
All relevant data are within the manuscript and its Supplementary Files.
3. Results
3.1. Clinical and Genetic Characterization of the Study Cohort
A cohort of 88 randomly selected bronchoalveolar lavage fluid (BALF) samples biobanked at the
Australian Respiratory Surveillance Team for Cystic Fibrosis (AREST-CF) in Perth (WA, Australia) were
used in this study. This paediatric cohort was from clinically stable preschool-aged patients ranging in
age from 2.5 to 4.4 years (median age 3.25; interquartile range (IQR) 2.938–3.86). Most of the patients
were diagnosed with CF at birth through newborn genetic screening (71 out of 88). The remaining
subjects presented with a range of conditions including meconium ileus (nine), failure to thrive
(seven), ecogenic fetal bowel (one), family history (one), or respiratory symptoms (two) including
respiratory syncytial virus positive bronchiolitis (one). Subjects in this study were identified with the
c.1521_1523delCTT (p.Phe508del) allele either in the homozygous (47%) or the heterozygous state.
Those patients harbouring the p.Phe508del mutation in heterozygosity were described with a second
pathogenic variant in the CFTR gene, with the exception of 4 cases in which a second deleterious allele
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was not reported (Supplementary Files). In cases in which the genetic screening was not positive CF
diagnosis was confirmed by a chloride sweat test result greater than 60 mmol L−1.
Patients were examined annually at periods of stability in respiratory symptoms. The majority of
samples were obtained during an annual follow up chest computed tomography (CT) scan procedure
(86 out of 88), except for two of them that were collected following Pseudomonas aeruginosa eradication
therapy. Clinical evaluation of the patients at the time of hospital visits included the collection of a
BALF sample, as well as a routine CT scan procedure. The BALF specimens were collected from the
right middle lobe following the established AREST-CF standard operating protocols. Cytokine and
inflammatory markers testing, clinical biochemistry measurements, white blood cell count and viability,
as well as clinical microbiology, were carried out on all of the BALF specimens immediately after
collection following the standardized AREST-CF protocols [23–25]. BALF supernatants obtained
after low speed centrifugation to pellet eukaryotic cells were then processed as single-use aliquots,
snap frozen and stored until further analysis.
3.2. Classification of the Paediatric Cohort Based on Bile Acid Profiles in BALF
In order to investigate whether the presence of BAs in the lower airways of CF patients
was associated with clinical outcomes, BALF samples were profiled for twelve individual BAs
including conjugated primary and secondary BAs broadly representative of human bile [16,26,33].
The concentrations of BAs detected, although lower than those reported by our group and others in
sputum or saliva [26,34], were consistent with previous reports from BALF [35] (Supplementary Files).
Importantly, the total concentration of BAs was not correlated with either the volume of saline instilled
into the lungs (Spearman ρ −0.08, p-value 0.43) or the volume of bronchial wash fluid recovered
(Spearman ρ −0.11, p-value 0.29), suggesting that our data is truly representative of the BA load in the
lower airways of these patients.
To better understand the biological significance of BA detection in the BALF of CF patients,
we grouped the samples into categories based on the resulting BAs profiles. For classification,
we carried out an unsupervised clustering approach using an agglomerative hierarchical cluster
model built applying Ward’s linkage method to a matrix of Euclidean distances. Thus, clustering is
unbiased relying solely on the BAs profile of each of the samples. To evaluate the goodness of the
different clustering solutions and therefore determine the optimal number of clusters from the model,
we applied two clustering validity approaches; the Calinski-Harabasz index [36] and the silhouette
coefficient [37,38]. A similar cluster validation approach was recently used for describing enterotypes
in the human gut microbiota [39]. Both internal clustering validation measures, agreed that the 2-cluster
outcome was the optimum solution for the sample classification problem (Figure 1A and Figure S1).
Next, we evaluated the characteristics of each cluster in the generated dendrogram. Upon closer
inspection, we observed that BALF samples classified in cluster 1 were characterized by significantly
higher levels of BAs than bronchial wash fluid specimens assigned to cluster 2 (cluster 1:
Median 0.058 µM, IQR 0.046–0.067; cluster 2: Median 0.018 µM, IQR 0.011–0.025. Mann-Whitney test,
p-value < 0.0001) (Figure 1B). Accordingly, the two clusters exhibited contrasting BA profiles. Thus,
while the composition of cluster 1 was mainly dominated by glycocholic acid (GCA) and to a lesser
extent by its conjugated dehydroxylated form glycodeoxycholic acid (GDCA), cluster 2 memberships
demonstrated that these two BAs were less abundant (Figure S2). Samples classified in the two clusters
were indistinguishable at the time of collection of the BALF specimen by age (Mann-Whitney test,
p-value = 0.6) or the therapeutic regimen, including β-lactam antibiotic treatment (augmentin, χ2 0.27,
degrees of freedom (df) 1, p-value = 0.6 and cephalexin, χ2 0.9, df 1, p-value = 0.34), non-antibiotic
medications (omeprazole, χ2 0.014, df 1, p-value = 0.9) or food supplements (calogen, χ2 0.59, df 1,
p-value = 0.44) among other prescribed medications (Supplementary Files).
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p-value < 0.0001. 
Figure 1. Cluster analysis of BALF samples based on their corresponding bile acids profiles.
(A) Heatmap showing the bile acid profiles for each BALF sample included in this study.
Columns represent individual samples and rows the different bile acid species profiled.
An agglomerative hierarchical clustering approach was applied for grouping the samples based
on Ward’s minimum variance method [28,29]. Colour key represents the concentration of each bile acid
profiled in micromolar (µM) scale. The side colour bar indicates whether the sample was included
in cluster 1 (red) or in cluster 2 (blue), after internal validation of the optimum number of clusters.
(B) Boxplots show the total bile acid concentration for cluster 1 and cluster 2. Asterisks indicate
statistical significance for the differences observed between clusters in the context of Mann-Whitney
test. **** p-value < 0.0001.
This sample classification strategy provided us with a practical framework to evaluate the biological
significance of bile acid detection in the lower airways of this paediatric CF cohort. Samples grouped
in cluster 2 were used in this study as age- and disease-matched internal controls to assess significant
relationships between bile acids and clinical outcomes. Following this comparative approach mitigated
the necessity to consider involving non-CF samples in the analysis.
3.3. Cluster 1 Membership Is Associated with Inflammatory Markers
We next evaluated whether the partitioning of the BALF samples based on BA composition was
associated with clinical outcomes in these patients. Samples in cluster 1 demonstrated significantly
higher levels of interleukin 1 beta (IL1β) and IL6. In contrast no significant differences were observed
in the production of neutrophil elastase (NE) or interleukin 8 (IL8) (Table 1).
Total cell burden in BALF did not show any significant relationship between cluster membership
and the relative abundance of specific immune cell lineages. Interestingly, we discovered that the
viability of the white blood cells present in the bronchial wash fluid was significantly reduced in
those specimens grouped in cluster 1 (Table 1). These observations are not confounded by intercluster
differences in residual CFTR activity as indicated by the results of the sweat chloride test in these patients
(cluster 1: median 90 mmol L−1, IQR 67.5–100.5; cluster 2: median 93 mmol L−1, IQR 67.5–102.25.
Mann-Whitney test, p-value = 0.929) (Figure S3). Despite the presentation of a pro-inflammatory
response, patients in cluster 1 did not exhibit a more severe lung structural deterioration as indicated by
volumetric CT scan-based scores including the recently reported PRAGMA-CF metrics [40] (Table 2).
Diagnostics 2020, 10, 282 6 of 12
Table 1. Quantification of inflammatory markers and white cell composition in the BALF
samples analysed in this study. Data represents the median value and the interquartile
range (1st quartile-3rd quartile) of each variable per cluster. Mann-Whitney test was used
for pairwise comparisons between group levels. Family-wise error rate was controlled using
Bonferroni-corrected p-values.
Variable Cluster 1 Cluster 2 p-Value
NE (ng mL−1) 100 (100–100) 100 (100–100) 1
IL8 (pg mL−1) 1075 (300–2150) 810 (250–1890) 1
IL1β (ng mL−1) 83.8 (54.44–122.52) 10 (10–32.58) 0.006
IL6 (ng mL−1) 57.79 (34.73–77.65) 10 (10–10) 0.041
Total cell count
(×106 cells mL−1 BALF) 0.32 (0.23–0.57) 0.29 (0.18–0.38) 1
% viability 74.8 (62.4–80.05) 82.8 (73.1–87.3) 0.038
% macrophages 83.33 (61.58–93.42) 86.67 (70.33–94) 1
% neutrophils 16.33 (6.58–38.24) 12 (4.33–29) 1
% lymphocytes 0 (0–0.33) 0 (0–1.67) 1
% eosinophils 0 (0–0.33) 0 (0–0.3) 1
Table 2. Quantification of structural lung disease at the time of the collection of the BALF samples
from patients classified in cluster 1 or cluster 2. Lung disease was scored using either volumetric CT
scans or the recently reported PRAGMA-CF methodology [40]. Calculated probabilities for rejecting
the null hypothesis of samples coming from the same population in the context of the Mann-Whitney
test were corrected for multiple comparisons using Bonferroni approach. BW, bronchial wall; Mu,
Mucus; %Dis, volume proportion of the lung with airway disease [40]; % Bx, volume proportion of the
lung with bronchiectasis [40]; %TA, volume proportion of the lung with trapped air [40], % Atelec,
volume proportion of the lung with atelectasis [40].
Variable Cluster 1 Cluster 2 p-Value
Bronchiectasis score 1 (0–2) 1 (0–3.5) 1
BW thickening score 10 (7–10) 8 (5–10) 1
Air trapped score 1 (0.75–4) 2 (1–4) 1
Mu. plugging score 0 (0–0.25) 0 (0–1) 1
% Dis 2.99 (2.39–4.13) 2.17 (1.1–3.8) 0.94
% Bx 0 (0–0.075) 0 (0–0.38) 1
% TA 2.06 (0.96–6.14) 1.28 (0.19–5.86) 1
% Atelec 0.06 (0–1.77) 0.2 (0–0.97) 1
Next, we investigated the detection of clinically relevant microorganisms that were cultured
from the BALF specimens collected from each patient included in this study (Supplementary Files).
According to the established AREST-CF protocols, clinical microbiology analysis is conducted separately
for the first wash aliquot from the right middle lobe, and for the bronchial wash fluid from the second
more affected lobe as per CT scan [23]. Data from both lobes was not combined but analysed separately.
We considered the detection of 10,000 colony-forming units per millilitre as indicative of pathogen
infection. This cut-off value has previously been shown to be a robust and reliable indicator of lower
airway infection using BALF specimens [41]. Although we did not detect any significant association
between infection by particular pathogens and cluster memberships in the right middle lobe, we did
however observe that the samples in cluster 1 were significantly associated with greater odds for
having positive cultures of oral flora in the left lobe (odds ratio OR 4.78, 95% confidence interval CI
1.62–14.15).
3.4. Cluster Membership Predicts the Progression of CF Lung Disease
Finally, we investigated whether cluster membership based on the detection of BAs in BALF could
predict the progression of CF lung disease. For this purpose, we analysed the available clinical data
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on the patient cohorts obtained from the subsequent follow up medical evaluation visit using linear
models. As expected, we observed that the proportion of the lungs with structural disease quantified
using PRAGMA metrics [40], had significantly increased during this follow up year period in our
patient cohort (Model 1, F(1,138) = 11.5, p-value < 0.05, multiple R2 0.07) (Table S1). Introduction of
the NE levels as an additional covariate resulted in a better fit of the model (Model 2 F(2,134) = 41.6,
p-value < 0.05, multiple R2 0.38), as indicated by the values of the Akaike Information Criterion (AIC)
and maximum likelihood estimators (Table S1). This result supports earlier research showing that
detection of NE activity in BALF of paediatric CF patients predicts the development and prognosis of
bronchiectasis [6,42]. Interestingly, the likelihood of the previous model to predict the progression of
lung disease was improved when the BA cluster membership was incorporated as an independent
categorical variable, with all the coefficients of the linear model being statistically significant at α = 0.05
level. This new linear model predicts an increase in the proportion of the lung with structural disease
over a period of one year, with a more pronounced progression in those patients belonging to cluster 1
(Model 3, F(3,133) = 31.1, p-value < 0.05, multiple R2 0.41) (Table S1).
To account for interindividual variability in the response and therefore not to underestimate the
total variance within our dataset, we also modelled the volume proportion of the lung with airway
disease as a function of time using linear mixed models. The outcome of this analysis indicated that the
fixed effects were approximately the same as for the standard linear regression. However, the likelihood
of the resulting models using random effects for the intercept (Model 4, AIC 558), random effects for
time (Model 5, AIC 558), or both (Model 6, AIC 562), was not improved with respect to the simplest
model without random effects (Table S2).
The use of BA profiles as a predictor of the prognosis of CF lung disease requires further refinement
for clinical consideration, particularly using longitudinal data. However, the predicted models indicate
that the presence of bile acids in the lower airways of our patient cohort is associated with a less
desirable disease trajectory in terms of lung structural damage.
4. Discussion
The present investigation provides experimental support to the hypothesis that BA
(micro)aspiration could be an important factor in the pathophysiology and progression of CF lung
disease in children. Bile acids are biological detergents that facilitate the digestion and absorption
of lipids and fat-soluble vitamins [43]. Apart from these functions, they are also involved in many
biological signalling and regulatory events, including metabolic tuning, modulation of the host immune
responses, control of microbial communities, and regulation of pathogenicity mechanisms in respiratory
pathogens [16,18,19,43–47]. Previous research has shown that the presence of BAs in BALF and sputum
from CF patients and lung transplant recipients is associated with inflammatory markers, suggesting a
role for BAs in the progression of CF respiratory disease and lung transplant rejection [34,35,48].
Our data expand these findings to paediatric CF patients where no consolidated structural lung disease
was observed. Using an unbiased clustering approach based on BA profiles, we observed strong
evidence associating the presence of BAs in BALF with inflammatory markers. We have reported
that BAs elicit an immune response in epithelial cells with increased levels of cytokines in tandem
with suppression of the HIF-1 signalling [16,19], which is known to be required for resolution of
acute inflammation [49]. Previously, we have also demonstrated that BA-mediated induction of
the pro-inflammatory cytokine IL6 was dependent on the BA receptor FXR [16]. This observation
provides a plausible mechanism to the higher levels of IL6 observed in the BALF samples contained in
cluster 1 of the present study. Furthermore, it has been shown in experimental animal models that
sustained production of IL1β triggers neutrophil infiltration, NE production, and lung inflammation
and fibrosis [50]. On the other hand, Esther and colleagues reported that the accumulation of inspissated
mucus gels in CF airways relates to hypoxia and inflammation [51]. Since inhaled noxa spark the
production of mucus by surface epithelial cells [52], bile acid translocation could exacerbate airway
inflammation by stimulating mucus secretion. Altogether, these observations may help to explain the
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more pronounced progression of lung disease observed in those patients classified in the cluster with
higher levels of BAs. Recently, new amino acid-conjugated cholic acid derivatives have been discovered
and found to be enriched in CF patients [53]. These newly characterized BA species activate FXR and
could further contribute to the dysregulation of the inflammatory response in CF [53]. Intriguingly,
we also observed a reduced viability in the white blood cells recovered from cluster 1-associated BALF
specimens. The homogeneity in the processing of BALF immediately after collection, and the unbiased
techniques used for sample classification based on BAs profiles, make it very unlikely that this result
could be as a consequence of the methodology employed. Bile acids are amphipathic molecules, some of
which can disrupt the cellular membrane of eukaryotic cells, induce oxidative stress and promote
apoptosis [54]. We have also demonstrated that bile activates a number of pathogenicity mechanisms
including type-VI secretion systems in classic airway pathogens such as Pseudomonas aeruginosa [17].
Apart from being involved in interbacterial communication, in rare occasions type-VI secretion systems
have also been shown to mediate host-pathogen interactions [55]. Moreover, the higher levels of IL1β
in cluster 1 may underpin toll-like receptor- or nod-like receptor-mediated activation of caspase-1,
which also triggers inflammatory programmed cell death [56]. Further studies are needed to ascertain
whether the observed reduced viability is a consequence of direct toxicity or the modulation of selected
pathogens in the lungs.
This work also raises a number of relevant questions regarding how BAs end up in the lungs
of CF patients. On the basis of the well-established associations between reflux and lung function
decline in many respiratory disorders, the available evidence would favour duodenal gastric reflux
and (micro)aspiration as the major sources of BAs found in the BALF of this patient cohort [20,21].
The (micro)aspiration hypothesis is further supported by the fact that: (i) BAs can be detected in
the gastric refluxate and saliva in humans [20,22], (ii) pepsin (another component of the gastric
refluxate) is present in the BALF of CF individuals [57], (iii) compared to healthy people, occurrence of
duodenal gastric reflux is high in CF patients [58] and a highly prevalent condition in CF children [21],
and (iv) reflux and aspiration are primary to the development of respiratory symptoms and dictate
the prognosis of lung disease [20]. In our cohort, BAs could also be derived from internal bleeding
associated with the collection procedure, or the presence of structural lung disease. Bleeding caused
by the medical procedure would be random. Thus, it would be very unlikely to observe the significant
associations that we are reporting. The second option can also be discarded because in our cohort,
patients discordant for BA concentration in BALF do have a similar degree of structural lung disease
(Table 2). Furthermore, BAs in the systemic circulation mainly come from distal intestinal absorption,
which is compromised in CF patients [59], and accordingly with newly synthesised BAs, we mainly
detected the glycine-conjugated primary BA GCA (Figure 1 and Figure S2).
Overall, the present study shows that the presence of BAs in the lungs of paediatric CF patients
associates with the modulation of a key event in the progression of lung disease, namely inflammation.
Mucins and inflammatory markers in BALF are considered to be early drivers of structural lung disease
in CF children [51]. It is currently not known if there is a relationship between BALF, mucus flakes and
bile acid profiles, and future mechanistic approaches will address this possibility. The outcome of such
studies could have important implications for developing possible preventative treatments to delay the
course of CF disease. The cross-sectional design of this study and the lack of a non-CF control cohort
do not permit us to establish the nature of the causal links or to determine whether the translocation of
BAs into the lungs is exclusive of children with CF. While we acknowledge this limitation, the reported
association results support the need for further investigations involving longitudinal and animal model
studies to dissect the mechanisms through which BAs modulate the progression of CF lung disease.
Supplementary Materials: The following are available online at http://www.mdpi.com/2075-4418/10/5/282/s1,
Supplementary Files: Sample metadata and bile acid profiles in BALF. Figure S1: Average silhouette coefficient for
the indicated number of clusters. Figure S2: Bile acid composition in the two groups of BALF samples. Figure S3:
Sweat chloride concentration for patients assigned to each cluster. Table S1: Regression results for the linear
models. Table S2: Regression results for the linear mixed effect models.
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